High plasma level of soluble RAGE is independently associated with a low recurrence of atrial fibrillation after catheter ablation in diabetic patient.
AIMS Atrial fibrillation (AF) is closely associated with metabolic syndrome, and the receptor for advanced glycation end products (RAGE) pathway is involved in insulin resistance and cardiac remodelling. We hypothesized that plasma level of soluble RAGE (sRAGE) would predict clinical outcome after radiofrequency catheter ablation for AF. METHODS AND RESULTS We measured pre procedural plasma level of sRAGE in 496 patients who underwent AF ablation (142 patients with diabetes, 354 patients without diabetes selected by matching them with diabetic patients according to age, sex, and AF type) (i) Plasma level of sRAGE was significantly higher in diabetic patients than in non diabetics (580.0 576.4 vs. 435.8 280.7 pg/mL, P 0.005) but there was no difference in sRAGE levels between patients with clinical recurrence of AF and those without. (ii) During 24.5 18.0 months of follow up, the recurrence of AF was significantly lower in the diabetic patient group with high sRAGE =418 pg/mL based on the median value) than the diabetic patient group with low sRAGE (log rank P 0.045) This was especially pronounced in patients with paroxysmal AF and diabetes (log rank P 0.016) but no association was found in non diabetics. (iii) In multivariate Cox regression analysis, high sRAGE (HR 0.395, 95% CI 0.175 0.894, P 0.026) and paroxysmal AF (HR 0.387, 95% CI 0.179 0.835, P 0.016) were independently associated with the favourable clinical outcome of rhythm control after AF ablation in diabetic patients. CONCLUSION High plasma level of sRAGE was independently associated with low AF recurrence after catheter ablation in diabetic patients, especially those with paroxysmal AF.
Europace European pacing, arrhythmias, and cardiac electrophysiology journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology